China Medical System Holdings (HKG:0867) said China's National Medical Products Administration approved its symptomatic obstructive hypertrophic cardiomyopathy (oHCM) drug, CMS-D003, for clinical trials, according to a Wednesday filing with the Hong Kong bourse.
CMS-D003 is a cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy by reducing excessive heart muscle contraction and improving heart function, the filing said.
The pharmaceutical's shares were up by almost 3% in recent trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.